Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis

NCT ID: NCT05183555

Last Updated: 2024-09-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-16
• Study Completion Date: 2024-06-18

Brief Summary

Study hypothesis: 68Ga-DOTATOC PET/CT could detect cardiac foci of infective endocarditis regardless of the type of valve (native or prosthetic) and also extracardiac localizations related to this pathology (infection responsible, peripheral emboli, ...). This study is a proof of concept with low population

Detailed Description

The incidence of infective endocarditis (IE) in France is estimated to be around 30 cases per million inhabitants in studies conducted in Western countries and is significantly increased in patients with a valve prosthesis and even more so in cases of a history of endocarditis. The morbi-mortality is significant and the hospital mortality rate is 20%.

The diagnosis of IE remains difficult and according to the modified Duke criteria, the diagnostic sensitivity is 80%.

Currently, the diagnosis of IE is often determined according to the 2015 ESC criteria and the sensitivity increases from 57% to 84% regarding IE on prosthetic valves.

The 18F-FDG PET/CT examination is of major interest in the diagnosis of AR on prosthetic valves with a detection sensitivity of between 70 and 90% (with an accuracy of 70 to 80%). Concerning native valves, the sensitivity of PET/CT remains below 50%.

Indeed, a "physiological" myocardial fixation in 18F-FDG PET/CT compromises the interpretation of PET exam, so it is important to start a hypoglycemic-hyperlipidic diet the day before the 18F-FDG PET/CT, followed by a 12-hour fasting period.

For several years, a radiopharmaceutical, 68Ga-DOTATOC (68Ga-edotreotide) has been used in PET/CT for the diagnosis and follow-up of neuroendocrine tumours (NETs). 68Ga-DOTATOC binds mainly with high affinity to somatostatin receptor subtype 2 (SSTR2) but also to somatostatin receptor subtype 5 (SSTR5).

Activated monocytes, macrophages, and lymphocytes express somatostatin receptors , thus detection of SSTR2 receptors expressed by inflammatory cells could help for the diagnosis of infective endocarditis.

PET/CT with 68Ga-DOTATOC could thus detect inflammatory cells at infectious sites. This radiopharmaceutical has already shown an ability to identify a myocardial inflammation (inflammatory phase myocarditis and cardiac sarcoidosis).

In current study conducted by our teams (NCT03347760 on ClinicalTrials.gov), early results showed the capacity of the 68Ga-DOTATOC to detect efficiently myocarditis, including myocarditis induced by RNA anti-COVID vaccinations.

In vitro, the 18FDG uptake by inflammatory cells is more important than the 68Ga-DOTATOC uptake, but the contrast between infection focus and healthy tissue should be better since 68Ga-DOTATOC does not cause any physiological myocardial uptake. The 68Ga-DOTATOC does not required any special metabolic preparation or prolonged fasting often poorly supported by patients.

Conditions

Infective Endocarditis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patients with definite IE will be included and referred for 18F-FDG PET/CT in the study

Fourteen patients with definite IE according to the modified Duke criteria (Li) will be included and referred for 18F-FDG PET/CT in the study. A 68Ga-DOTATOC PET/CT scan will be performed specifically for research at 24 hours.

Group Type: EXPERIMENTAL

68Ga-DOTATOC PET/CT

Intervention Type: DRUG

68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent

Interventions

68Ga-DOTATOC PET/CT

68Ga-DOTATOC PET/CT will be recorded the following day of 18F-FDG PET/CT if patient signed the consent

Intervention Type: DRUG

Other Intervention Names

18F-FDG PET/CT

Eligibility Criteria

Inclusion Criteria

• Adult who has received full information about the organisation of the research and has signed informed consent adult
• Participant hospitalised for definite AE according to modified Duke criteria (Li), on native or prosthetic valve, referred for 18F-FDG PET/CT from Cardiology and Infectious Diseases departments

Exclusion Criteria

• Person with a history of hypersensitivity from previous use of 68Ga-DOTATOC
• Unable to perform a 68Ga-DOTATOC PET scan (agitated, confused patient...).
• Inability to schedule 68Ga-DOTATOC PET/CT the day after 18F-FDG PET/CT.
• Person with severe renal impairment (GFR <30 ml/min/1.73 m2)
• Participant treated with a somatostatin analogue.
• Participant with Cushing's syndrome
• Pregnant, potentially pregnant or breastfeeding women
• Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)
• Person of full age who is unable to give consent
• Person deprived of liberty by a judicial or administrative decision
• Person subject to psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Central Hospital, Nancy, France

OTHER

Sponsor Role: lead

Responsible Party

BOURSIER Caroline

Principal investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

CHRU de NANCY

Vandœuvre-lès-Nancy, , France

Countries

France

Other Identifiers

2021PI119

Identifier Type: -

Identifier Source: org_study_id